TY - JOUR
TI - Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The hellenic experience
AU - Siakantaris, M.P.
AU - Tsirigotis, P.
AU - Stavroyianni, N.
AU - Argyropoulos, K.V.
AU - Girkas, K.
AU - Pappa, V.
AU - Chondropoulos, S.
AU - Papadavid, E.
AU - Sakellari, I.
AU - Anagnostopoulos, A.
AU - Antoniou, C.
AU - Dervenoulas, J.
JO - Transfusion and Apheresis Science
PY - 2012
VL - 46
TODO - 2
SP - 189-193
PB - 
SN - 1473-0502
TODO - 10.1016/j.transci.2011.10.029
TODO - alpha interferon;  bexarotene;  denileukin diftitox;  pentostatin, adult;  aged;  article;  cancer survival;  clinical article;  clinical trial;  cutaneous T cell lymphoma;  extracorporeal photopheresis;  female;  follow up;  human;  male;  progression free survival;  PUVA;  survival time;  treatment outcome;  treatment response, Adult;  Aged;  Disease-Free Survival;  Female;  Follow-Up Studies;  Humans;  Immunologic Factors;  Lymphoma, T-Cell, Cutaneous;  Male;  Middle Aged;  Photopheresis;  Skin Neoplasms;  Survival Rate
TODO - Extracorporeal photopheresis (ECP) is an established therapy for cutaneous T-cell lymphoma (CTCL). The objective of this study was to further explore the clinical efficacy of ECP combined with immunomodulatory agents.Eighteen patients with histologically proven CTCL were followed-up after therapy with ECP, mainly combined with interferon-α or bexarotene.A total of 61% of patients responded to therapy (n=11; CR: 5, PR: 6). Median survival was 51. months, progression free survival was 28. months and response duration was 29±23.9. months.ECP combined therapy was highly effective or had a palliative effect in CTCL resistant to previous treatments. © 2011.
ER -